Zhejiang Jingxin Pharmaceutical Co., Ltd.

China

Back to Profile

1-22 of 22 for Zhejiang Jingxin Pharmaceutical Co., Ltd. Sort by
Query
Aggregations
IP Type
        Patent 21
        Trademark 1
Jurisdiction
        World 16
        United States 4
        Canada 2
Date
New (last 4 weeks) 1
2025 March (MTD) 1
2025 January 1
2025 (YTD) 2
2024 4
See more
IPC Class
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia 7
A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia 6
A61P 25/22 - Anxiolytics 6
C07D 333/66 - Nitrogen atoms not forming part of a nitro radical 6
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin 5
See more
NICE Class
01 - Chemical and biological materials for industrial, scientific and agricultural use 1
05 - Pharmaceutical, veterinary and sanitary products 1
Status
Pending 3
Registered / In Force 19

1.

FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR

      
Application Number 18724209
Status Pending
Filing Date 2022-12-26
First Publication Date 2025-03-06
Owner
  • SHANGHAI JINGXIN BIOMEDICAL CO., LTD. (China)
  • ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD. (China)
Inventor
  • Jiang, Qingyun
  • Fang, Xin
  • Li, Ping
  • Li, Ningning
  • Xie, Zhihan
  • Wu, Yinhui
  • Ma, Ningtian
  • Hou, Jian

Abstract

Provided are a fused bicyclic heteroaryl amide compound as a protein aggregation inhibitor, as well as the use of such compound in the treatment or prevention of neurodegenerative diseases characterized by protein aggregation, such as Alzheimer's disease, Parkinson's disease, frontotemporal dementia, dementia with Lewy bodies, Parkinson's disease dementia, multiple system atrophy, amyotrophic lateral sclerosis, Huntington's disease, and cancer.

IPC Classes  ?

  • C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
  • A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
  • A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
  • A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
  • A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
  • A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
  • C07D 471/10 - Spiro-condensed systems
  • C07D 487/10 - Spiro-condensed systems
  • C07D 491/10 - Spiro-condensed systems
  • C07D 495/04 - Ortho-condensed systems

2.

CRYSTAL FORM OR SALT OF BICYCLIC HETEROARYL AMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF

      
Application Number CN2024100904
Publication Number 2025/002040
Status In Force
Filing Date 2024-06-24
Publication Date 2025-01-02
Owner
  • SHANGHAI JINGXIN BIOMEDICAL CO., LTD. (China)
  • ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD. (China)
Inventor
  • Zhou, Xinbo
  • Wang, Yongting
  • Song, Lihua

Abstract

The present invention provides a crystal form or salt of a bicyclic heteroaryl amide compound, a preparation method therefor and a use thereof. Specifically, the present invention relates to a crystal form or salt of a compound of general formula (I) or a stereoisomer of said compound, a preparation method therefor and a use thereof in treating or preventing neurodegenerative diseases characterized by protein aggregation.

IPC Classes  ?

  • C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
  • C07D 209/04 - IndolesHydrogenated indoles
  • C07D 487/02 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains two hetero rings
  • C07D 495/02 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D 247/00 - Heterocyclic compounds containing rings having two nitrogen atoms as the only ring hetero atoms, according to more than one of groups
  • C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
  • A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61P 25/16 - Anti-Parkinson drugs

3.

RNAI AGENT FOR INHIBITING EXPRESSION OF LPA AND USE OF RNAI AGENT

      
Application Number CN2024089357
Publication Number 2024/222686
Status In Force
Filing Date 2024-04-23
Publication Date 2024-10-31
Owner
  • SHANGHAI JINGXIN BIOMEDICAL CO., LTD. (China)
  • ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD. (China)
Inventor
  • Ni, Shuaijian
  • Song, Ying

Abstract

Provided is an RNAi agent for inhibiting the expression of apolipoprotein (a) gene (LPA) in a cell. The RNAi agent comprises a sense strand and an antisense strand which form a double-stranded region. The antisense strand has a length of no more than 23 nucleotides and comprises any nucleotide sequence selected from SEQ ID NOs: 265 to 528. Also provided is a use of the RNAi agent in treatment of cardiovascular and cerebrovascular diseases, etc.

IPC Classes  ?

  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
  • A61P 3/06 - Antihyperlipidemics
  • A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
  • A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
  • A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
  • A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose

4.

CYCLIC AMINE DERIVATIVE, AND COMPOSITION AND USE THEREOF

      
Application Number CN2024082950
Publication Number 2024/199070
Status In Force
Filing Date 2024-03-21
Publication Date 2024-10-03
Owner
  • SHANGHAI JINGXIN BIOMEDICAL CO., LTD. (China)
  • ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD. (China)
Inventor
  • Ni, Shuaijian
  • Song, Ying
  • Tang, Jiaqi

Abstract

The present invention relates to a cyclic amine derivative or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the cyclic amine derivative or the pharmaceutically acceptable salt thereof, and the use of the cyclic amine derivative or the pharmaceutically acceptable salt thereof or the composition thereof. The cyclic amine derivative of the present invention has a relatively strong capacity of binding to apo(a), can effectively reduce the level of Lp(a), and has low toxic side effects.

IPC Classes  ?

  • C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
  • C07D 207/08 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
  • A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
  • A61P 3/06 - Antihyperlipidemics

5.

CYCLOHEXANE DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF

      
Application Number CN2024076274
Publication Number 2024/165013
Status In Force
Filing Date 2024-02-06
Publication Date 2024-08-15
Owner
  • SHANGHAI JINGXIN BIOMEDICAL CO., LTD. (China)
  • ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD. (China)
Inventor
  • Sang, Yingxia
  • Bao, Ziyang
  • Ma, Yuqin

Abstract

131A1A receptor, for the treatment of neuropsychiatric diseases, and has low toxicity.

IPC Classes  ?

  • C07D 333/54 - Benzo [b] thiophenesHydrogenated benzo [b] thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
  • C07D 333/72 - Benzo [c] thiophenesHydrogenated benzo [c] thiophenes
  • C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
  • A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
  • A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
  • A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
  • A61P 25/22 - Anxiolytics
  • A61P 25/24 - Antidepressants
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

6.

LIGAND-OLIGONUCLEOTIDE CONJUGATE AND LINKER FOR CONJUGATE

      
Application Number CN2023125626
Publication Number 2024/083220
Status In Force
Filing Date 2023-10-20
Publication Date 2024-04-25
Owner
  • SHANGHAI JINGXIN BIOMEDICAL CO., LTD. (China)
  • ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD. (China)
Inventor
  • Ni, Shuaijian
  • Song, Ying
  • Jing, Xi
  • Liu, Zixuan

Abstract

A ligand-oligonucleotide conjugate and a linker for the conjugate, the linker including the structure of formula I or II: -NR1-C(O)-[C(R3R4nn-C(O)-[NR2-C(RaRbpp- (formula I), or -NR1-[C(O)-C(RaRb)-NR2pp-C(O)-[C(R3R4nn-C(O)- (formula II). Also provided are a preparation method for the conjugate, and an intermediate.

IPC Classes  ?

  • A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
  • A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

7.

FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR

      
Application Number CN2022141820
Publication Number 2023/125376
Status In Force
Filing Date 2022-12-26
Publication Date 2023-07-06
Owner
  • SHANGHAI JINGXIN BIOMEDICAL CO., LTD. (China)
  • ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD. (China)
Inventor
  • Jiang, Qingyun
  • Fang, Xin
  • Li, Ping
  • Li, Ningning
  • Xie, Zhihan
  • Wu, Yinhui
  • Ma, Ningtian
  • Hou, Jian

Abstract

Provided are a fused bicyclic heteroaryl amide compound as a protein aggregation inhibitor, as well as the use of such compound in the treatment or prevention of neurodegenerative diseases characterized by protein aggregation, such as Alzheimer's disease, Parkinson's disease, frontotemporal dementia, dementia with Lewy bodies, Parkinson's disease dementia, multiple system atrophy, amyotrophic lateral sclerosis, Huntington's disease, and cancer.

IPC Classes  ?

  • C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
  • C07D 209/04 - IndolesHydrogenated indoles
  • C07D 487/02 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains two hetero rings
  • C07D 495/02 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D 247/00 - Heterocyclic compounds containing rings having two nitrogen atoms as the only ring hetero atoms, according to more than one of groups
  • C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
  • A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61P 25/16 - Anti-Parkinson drugs

8.

Salt of cyclohexane derivative

      
Application Number 17267160
Grant Number 11584731
Status In Force
Filing Date 2019-08-13
First Publication Date 2021-10-07
Grant Date 2023-02-21
Owner
  • Shanghai Jingxin Biology & Pharmaceutical Co., Ltd (China)
  • Zhejiang Jingxin Pharmaceutical Co., Ltd. (China)
Inventor
  • Huang, Yue
  • Zheng, Fei
  • Fu, Xiaoyun
  • Tang, Chunlan
  • Zhu, Dan

Abstract

The present invention provides a maleate, phosphate, sulfate, hydrochloride of a cyclohexane derivative, N′-[trans-4-[2-[7-(benzo[b]thiophene)-7-piperazinyl]ethyl]cyclohexyl]-N,N-dimethylurea, as shown in Formula I and crystal forms thereof. The crystal forms have low hygroscopicity and good stability and are convenient for long-term storage and transportation; or the crystal forms have a long half-life in vivo, high bioavailability and small individual difference, and thus have obvious clinical application advantages.

IPC Classes  ?

  • C07D 333/66 - Nitrogen atoms not forming part of a nitro radical
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond

9.

BLOOD COAGULATION FACTOR XIA INHIBITOR

      
Application Number CN2020141466
Publication Number 2021/136390
Status In Force
Filing Date 2020-12-30
Publication Date 2021-07-08
Owner
  • SHANGHAI JINGXIN BIOMEDICAL CO., LTD. (China)
  • ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD. (China)
Inventor
  • An, Dong
  • Liu, Yu
  • Luo, Qinghe
  • Zhang, Bin
  • Miao, Shuai
  • Wu, Guangsheng
  • Lu, Kai

Abstract

A blood coagulation factor XIa inhibitor of formula I, a pharmaceutical composition containing same, a preparation method therefor, and use thereof in preparation of drugs for prevention or treatment of thrombosis and embolism-related diseases.

IPC Classes  ?

  • C07D 257/06 - Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
  • C07D 471/00 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups
  • C07D 487/00 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups
  • A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
  • A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors
  • A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

10.

SALT OF CYCLOHEXANE DERIVATIVE

      
Application Number CN2019100366
Publication Number 2020/042903
Status In Force
Filing Date 2019-08-13
Publication Date 2020-03-05
Owner
  • ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD. (China)
  • SHANGHAI JINGXIN BIOLOGY & PHARMACEUTICAL CO., LTD (China)
Inventor
  • Huang, Yue
  • Zheng, Fei
  • Fu, Xiaoyun
  • Tang, Chunlan
  • Zhu, Dan

Abstract

The present invention provides a maleate, phosphate, sulfate, and hydrochloride of a cyclohexane derivative, N'-[trans-4-[2-[7-(benzo[b]thiophene)-7-piperazinyl]ethyl]cyclohexyl]-N,N-dimethylurea, as shown in formula I and crystal forms thereof. The crystal forms have low hygroscopicity and good stability and are convenient for long-term storage and transportation; or the crystal forms have a long half-life in vivo, high bioavailability, and small individual differences, and thus have obvious clinical application advantages.

IPC Classes  ?

  • C07D 333/66 - Nitrogen atoms not forming part of a nitro radical
  • A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
  • A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
  • A61P 25/24 - Antidepressants
  • A61P 25/22 - Anxiolytics
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

11.

SALT OF CYCLOHEXANE DERIVATIVE

      
Document Number 03110131
Status Pending
Filing Date 2019-08-13
Open to Public Date 2020-03-05
Owner
  • SHANGHAI JINGXIN BIOLOGY & PHARMACEUTICAL CO., LTD (China)
  • ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD. (China)
Inventor
  • Huang, Yue
  • Zheng, Fei
  • Fu, Xiaoyun
  • Tang, Chunlan
  • Zhu, Dan

Abstract

The present invention provides a maleate, phosphate, sulfate, and hydrochloride of a cyclohexane derivative, N'-[trans-4-[2-[7-(benzo[b]thiophene)-7-piperazinyl]ethyl]cyclohexyl]-N,N-dimethylurea, as shown in formula I and crystal forms thereof. The crystal forms have low hygroscopicity and good stability and are convenient for long-term storage and transportation; or the crystal forms have a long half-life in vivo, high bioavailability, and small individual differences, and thus have obvious clinical application advantages.

IPC Classes  ?

  • C07D 333/66 - Nitrogen atoms not forming part of a nitro radical
  • A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
  • A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
  • A61P 25/22 - Anxiolytics
  • A61P 25/24 - Antidepressants
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

12.

METHOD FOR PREPARING CYCLOHEXANE DERIVATIVE

      
Application Number CN2019100364
Publication Number 2020/034945
Status In Force
Filing Date 2019-08-13
Publication Date 2020-02-20
Owner
  • ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD. (China)
  • SHANGHAI JINGXIN BIOLOGY & PHARMACEUTICAL CO., LTD. (China)
Inventor
  • Huang, Yue
  • Zheng, Fei
  • Xu, Hui

Abstract

The present invention provides a method for preparing a cyclohexane derivative, comprising the following steps: (1) subjecting a compound SM01 and a compound SM02 or a salt thereof to a nucleophilic substitution reaction to obtain a compound A; (2) deprotecting the compound A to obtain a compound B; and (3) subjecting the compound B and an acylation reagent to an acylation reaction to obtain a cyclohexane derivative. The method provided by the present invention has less side reactions, high product yield, and high product purity, and are suitable for industrial-scale production.

IPC Classes  ?

  • C07D 261/20 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
  • C07D 275/04 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
  • C07D 333/66 - Nitrogen atoms not forming part of a nitro radical
  • C07D 333/72 - Benzo [c] thiophenesHydrogenated benzo [c] thiophenes

13.

METHOD FOR PREPARING CYCLOHEXANE DERIVATIVE

      
Application Number CN2019100365
Publication Number 2020/034946
Status In Force
Filing Date 2019-08-13
Publication Date 2020-02-20
Owner
  • ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD. (China)
  • SHANGHAI JINGXIN BIOLOGY & PHARMACEUTICAL CO., LTD. (China)
Inventor
  • Huang, Yue
  • Zheng, Fei
  • Xu, Hui

Abstract

Provided is a method for preparing a cyclohexane derivative, the method comprising the following steps: subjecting a compound, 2-(4-(3,3-dimethylureido)cyclohexyl)acetaldehyde, represented by formula SM01 and a compound represented by formula SM02 to a condensation imine reduction reaction to obtain the cyclohexane derivative. The method of the present invention has few side reactions, a high product yield and a high product purity, and is favorable for the industrial scale production.

IPC Classes  ?

  • C07D 261/20 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
  • C07D 275/04 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
  • C07D 333/06 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulfur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
  • C07D 333/72 - Benzo [c] thiophenesHydrogenated benzo [c] thiophenes

14.

BENZODIAZEPINE COMPOUND SOLID FORMS, AND PREPARATION METHODS THEREFOR AND APPLICATIONS THEREOF

      
Application Number CN2018092820
Publication Number 2019/001414
Status In Force
Filing Date 2018-06-26
Publication Date 2019-01-03
Owner ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD (China)
Inventor
  • Zhou, Xinbo
  • Zhu, Jianrong
  • Xie, Zuonian
  • Ren, Xiaojuan

Abstract

Disclosed are novel solid forms of 7-chloro-3-(5-dimethylaminomethyl-[1,2,4]oxadiazol-3-yl)-5-methyl-4,5-dihydro-imidazo[1,5-a][1,4]benzodiazepin-6-one, comprising crystalline form A, crystalline form B and an amorphous form. Also disclosed are preparation methods for the solid forms, and applications of the solid forms in the preparation of anxiolytics and/or anticonvulsants and/or non-sedative hypnotics.

IPC Classes  ?

  • C07D 487/04 - Ortho-condensed systems
  • A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
  • A61P 25/22 - Anxiolytics
  • A61P 25/08 - AntiepilepticsAnticonvulsants

15.

STABLE ORAL PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR

      
Application Number CN2018091940
Publication Number 2018/192590
Status In Force
Filing Date 2018-06-20
Publication Date 2018-10-25
Owner ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD (China)
Inventor
  • Gao, Huiyan
  • Zhang, Lifeng
  • Chen, Jianyang

Abstract

Disclosed are a stable oral pharmaceutical composition and a preparation method therefor. The composition contains an effective amount of a compound having the structure shown in formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, the pharmaceutically acceptable carrier comprising a polymer having a melting point, glass transition temperature and softening temperature of less than 180°C, the mass ratio of the polymer with respect to the compound having the structure shown in formula I or the pharmaceutically acceptable salt thereof being more than 1.

IPC Classes  ?

  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
  • A61K 47/38 - CelluloseDerivatives thereof
  • A61K 9/20 - Pills, lozenges or tablets
  • A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
  • A61P 25/20 - HypnoticsSedatives

16.

Substituted ureas and methods of treating mental illness using the same

      
Application Number 15759119
Grant Number 10301277
Status In Force
Filing Date 2016-09-14
First Publication Date 2018-10-18
Grant Date 2019-05-28
Owner
  • ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD. (China)
  • SHANGHAI JINGXIN BIOMEDICAL CO., LTD. (China)
  • SHANGYU JINGXIN PHARMACEUTICAL CO., LTD. (China)
Inventor
  • Huang, Yue
  • Zheng, Fei

Abstract

2 receptors, and can be used as a therapeutic drug against neuropsychiatric diseases. wherein; X is N or CH; R is 6 alkyl is optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, and I.

IPC Classes  ?

  • C07C 275/26 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
  • C07D 333/54 - Benzo [b] thiophenesHydrogenated benzo [b] thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
  • C07D 333/72 - Benzo [c] thiophenesHydrogenated benzo [c] thiophenes
  • C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
  • A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
  • A61K 9/20 - Pills, lozenges or tablets
  • A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • C07D 261/20 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
  • C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
  • C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
  • C07D 275/04 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems

17.

GENETICALLY ENGINEERED BACTERIUM OF COEXPRESSING CYCLOHEXANONE MONOOXYGENASE AND ISOPROPANOL DEHYDROGENASE AND USE THEREOF

      
Application Number CN2017113011
Publication Number 2018/113476
Status In Force
Filing Date 2017-11-27
Publication Date 2018-06-28
Owner
  • ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD. (China)
  • SHANGHAI JINGXIN BIOLOGY & PHARMACEUTICAL CO., LTD. (China)
Inventor
  • Jin, Shengfang
  • Zhang, Minjie
  • Huang, Yue

Abstract

The present invention provides a genetically engineered bacterium of coexpressing cyclohexanone monooxygenase and isopropanol dehydrogenase and use thereof, and the genetically engineered bacterium constructed can catalyze and convert high-concentration omeprazole sulfide into esomeprazole.

IPC Classes  ?

  • C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
  • C12N 15/70 - Vectors or expression systems specially adapted for E. coli
  • C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
  • C12N 9/04 - Oxidoreductases (1.), e.g. luciferase acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
  • C12P 17/16 - Preparation of heterocyclic carbon compounds with only O, N, S, Se, or Te as ring hetero atoms containing two or more hetero rings

18.

CRYSTAL FORM OF TASIMELTEON

      
Application Number CN2017074030
Publication Number 2017/193662
Status In Force
Filing Date 2017-02-19
Publication Date 2017-11-16
Owner ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD. (China)
Inventor
  • Zhu, Jianrong
  • Peng, Chunyong
  • Zhong, Hongban
  • Hu, Xiurong

Abstract

Crystal forms I and II of tasimelteon. Crystal form I: an X-ray powder diffraction spectrum using CuKα radiation and represented by a 2θ angle has diffraction peaks at least at 7.2º±0.2º, 7.9º±0.2º, 10.6º±0.2º, 14.4º±0.2º, 15.9º±0.2º, 17.3º±0.2º, 21.0º±0.2º, 23.2º±0.2º, and 24.4º±0.2º. Crystal form II: an X-ray powder diffraction spectrum using CuKα radiation and represented by a 2θ angle has diffraction peaks at least at 6.8º±0.2º, 12.1º±0.2º, 12.5º±0.2º, 13.1º±0.2º, 13.6º±0.2º, 13.8º±0.2º, 15.8º±0.2º, 17.0º±0.2º, 18.4º±0.2º, 20.8º±0.2º, 24.2º±0.2º, and 24.4º±0.2º. Crystal forms I and II of tasimelteon have advantages of excellent physicochemical property, good stability and solubility, and simple operation for preparation.

IPC Classes  ?

  • C07D 307/79 - Benzo [b] furansHydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
  • A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
  • A61P 25/20 - HypnoticsSedatives

19.

CYCLOHEXANE DERIVATIVE OR STEREOISOMER OR SALT THEREOF, AND PREPARATION AND USE THEREOF

      
Document Number 02998758
Status Pending
Filing Date 2016-09-14
Open to Public Date 2017-03-23
Owner
  • ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD. (China)
  • SHANGHAI JINGXIN BIOMEDICAL CO., LTD. (China)
  • SHANGYU JINGXIN PHARMACEUTICAL CO., LTD. (China)
Inventor
  • Huang, Yue
  • Zheng, Fei

Abstract

Provided are a cyclohexane derivative as shown by formula IB or a stereoisomer or a salt thereof, and the preparation and use thereof. The cyclohexane derivative has a high affinity for D3 receptors and 5-hydroxytryptamine, has a lower affinity for D2 receptors, shows a high selectivity for D3/D2 receptors, and can be used as a therapeutic drug against neuropsychiatric diseases wherein X is N or -CH-; where R group is optionally substituted with one or more substituents selected from halogen and Ci-Ce alkyl; and further where the Ci-Ce alkyl is optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br and I.

IPC Classes  ?

  • C07D 333/54 - Benzo [b] thiophenesHydrogenated benzo [b] thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
  • A61K 31/4523 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
  • C07D 333/66 - Nitrogen atoms not forming part of a nitro radical
  • C07D 333/72 - Benzo [c] thiophenesHydrogenated benzo [c] thiophenes
  • C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
  • C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
  • A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
  • A61P 25/22 - Anxiolytics
  • A61P 25/24 - Antidepressants
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

20.

CYCLOHEXANE DERIVATIVE OR STEREOISOMER OR SALT THEREOF, AND PREPARATION AND USE THEREOF

      
Application Number CN2016098953
Publication Number 2017/045599
Status In Force
Filing Date 2016-09-14
Publication Date 2017-03-23
Owner
  • ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD. (China)
  • SHANGHAI JINGXIN BIOMEDICAL CO.,LTD. (China)
  • SHANGYU JINGXIN PHARMACEUTICAL CO.,LTD. (China)
Inventor
  • Huang, Yue
  • Zheng, Fei

Abstract

Provided are a cyclohexane derivative as shown by formula IB or a stereoisomer or a salt thereof, and the preparation and use thereof. The cyclohexane derivative has a high affinity for D3 receptors and 5-hydroxytryptamine, has a lower affinity for D2 receptors, shows a high selectivity for D3/D2 receptors, and can be used as a therapeutic drug against neuropsychiatric diseases; and the preparation method thereof is simple and easy.

IPC Classes  ?

  • C07D 333/54 - Benzo [b] thiophenesHydrogenated benzo [b] thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
  • C07D 333/66 - Nitrogen atoms not forming part of a nitro radical
  • C07D 333/72 - Benzo [c] thiophenesHydrogenated benzo [c] thiophenes
  • C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
  • A61K 31/4523 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
  • A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
  • A61P 25/24 - Antidepressants
  • A61P 25/22 - Anxiolytics
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

21.

Treatment of sleep disorders

      
Application Number 14244085
Grant Number 10370378
Status In Force
Filing Date 2014-04-03
First Publication Date 2014-08-14
Grant Date 2019-08-06
Owner ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD. (China)
Inventor
  • Kemp, John Alan
  • Hunneyball, Ian Michael
  • Tasker, Timothy

Abstract

The use of 7-chloro-3-(5-dimethylaminomethyl-[1,2,4]oxadiazol-3-yl)-5methyl-4,5-dihydro-imidazol[1,5,-a][1,4]benzodiazepine-6-one or its pharmaceutically acceptable salt for treating various types of insomnia.

IPC Classes  ?

  • C07D 487/04 - Ortho-condensed systems
  • A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam

22.

Miscellaneous Design

      
Application Number 827567
Status Registered
Filing Date 2003-12-20
Registration Date 2003-12-20
Owner ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD. (China)
NICE Classes  ?
  • 01 - Chemical and biological materials for industrial, scientific and agricultural use
  • 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Raw materials (for medicine). Pharmaceutical preparations; chemico-pharmaceutical preparations; vitamin preparations; suppositories; medicines for human purposes; preparations of trace elements for human and animal use; injection; medicine (piece); medicinal extract; traditional chinese medicines (prepared by a pharmacy); medicinal gum; veterinary preparations; medicines for veterinary purposes; chemical preparations for veterinary purposes.